Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H16ClNO2S.ClH |
Molecular Weight | 358.283 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=CC=CC=C3Cl
InChI
InChIKey=XIHVAFJSGWDBGA-RSAXXLAASA-N
InChI=1S/C16H16ClNO2S.ClH/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;/h2-5,7,9,15H,6,8,10H2,1H3;1H/t15-;/m0./s1
Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct
inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that
inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the
binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet
aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active
metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet
aggregation induced by agonists other than ADP is also inhibited by blocking the amplification
of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
6.9 null [pKi] | |||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia.
Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Preventing | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1500 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
15800 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2520 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4600 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.521 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3130 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
50600 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7440 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
9890 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.767 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
1.09 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
unknown, unknown |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: |
Other AEs: Uric acid abnormal... |
1650 mg single, oral Overdose Dose: 1650 mg Route: oral Route: single Dose: 1650 mg Co-administed with:: phenytoin sodium(1400 mg; single) Sources: simvastatin(120 mg; single) |
unknown, 49 years n = 1 Health Status: unknown Age Group: 49 years Sex: M Population Size: 1 Sources: |
|
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Disc. AE: Transaminases increased, Fever... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Fever (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Uric acid abnormal | 5 patients | 600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: |
Fever | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Transaminases increased | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Drug-induced thrombotic microangiopathy: incidence, prevention and management. | 2001 |
|
Atherothrombosis: a major health burden. | 2001 |
|
Novel platelet inhibitors. | 2001 |
|
The use of antiplatelet agents in acute cardiac care. | 2001 Apr |
|
Aspirin in patients with coronary artery disease: is it simply irresistible? | 2001 Apr |
|
CURE--clopidogrel's major advance. | 2001 Apr |
|
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]. | 2001 Apr |
|
[Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors]. | 2001 Apr |
|
Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease. | 2001 Apr |
|
Bench to bedside: the development of rapamycin and its application to stent restenosis. | 2001 Aug 21 |
|
Severe hypersensitivity associated with clopidogrel. | 2001 Aug 21 |
|
Newer antiplatelet therapies in stroke prevention. | 2001 Feb |
|
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists. | 2001 Feb |
|
Thrombolysis and antithrombotic therapy for coronary artery disease. | 2001 Feb |
|
Antithrombotic and thrombolytic therapy for ischemic stroke. | 2001 Feb |
|
Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. | 2001 Feb 1 |
|
Fatal aplastic anaemia associated with clopidogrel. | 2001 Feb 10 |
|
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. | 2001 Feb 15 |
|
[Clopidogrel? Known or known?]. | 2001 Jan |
|
Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. | 2001 Jan |
|
[2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]]. | 2001 Jan 11 |
|
Identification of the platelet ADP receptor targeted by antithrombotic drugs. | 2001 Jan 11 |
|
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. | 2001 Jan 23 |
|
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. | 2001 Jan 25 |
|
Febrile pancytopenia associated with clopidogrel. | 2001 Jan 8 |
|
Clopidogrel (Plavix): hematological reactions. | 2001 Jan 9 |
|
The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease. | 2001 Jul |
|
Extensive thrombus prior to elective percutaneous coronary intervention. | 2001 Jul |
|
Diffuse alveolar hemorrhage after clopidogrel use. | 2001 Jul |
|
The P2Y12 receptor as a therapeutic target in cardiovascular disease. | 2001 Jun |
|
[Toxic skin reaction to clopidogrel]. | 2001 Jun |
|
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy]. | 2001 Mar |
|
[Acute coronary syndromes: an update. II. Coronary revascularization and risk stratification]. | 2001 Mar |
|
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. | 2001 Mar |
|
[Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery]. | 2001 May |
|
The inhibition of oxygen radical release from human neutrophils by resting platelets is reversed by administration of acetylsalicylic acid or clopidogrel. | 2001 May |
|
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. | 2001 May |
|
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings. | 2001 May 1 |
|
Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). | 2001 May 15 |
|
P2y(12), a new platelet ADP receptor, target of clopidogrel. | 2001 May 4 |
|
Clopidogrel and aplastic anaemia. | 2001 May 5 |
|
Prospective controlled study of carotid endarterectomy with hemashield patch: is it thrombogenic? | 2001 May-Jun |
|
Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. | 2001 Nov 1 |
|
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. | 2001 Oct |
|
Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting. | 2001 Oct |
|
Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. | 2001 Sep |
|
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. | 2001 Sep |
|
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. | 2001 Sep |
|
Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. | 2001 Sep |
|
Complications of oral antiplatelet medications. | 2001 Sep |
Sample Use Guides
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
The recommended daily dose of is 75 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10077233
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-TAD (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-HCS (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA D.D. (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA PHARMA (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TAD (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-HCS (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL DURA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL QUALIMED (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL QUALIMED (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-DURA (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL MYLAN (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA PHARMA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA D.D. (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-KRKA (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA D.D. (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL QUALIMED (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL DURA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
NCI_THESAURUS |
C80483
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA PHARMA (AUTHORIZED: AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-HCS (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL MYLAN (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TAD (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HCS (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL MYLAN (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT002594
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
PRIMARY | |||
|
100000115888
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
PRIMARY | |||
|
120202-65-5
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
PRIMARY | |||
|
9798860
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
PRIMARY | |||
|
426O7XWS6Y
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
PRIMARY | |||
|
C96893
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
PRIMARY | |||
|
SUB30779
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
PRIMARY | |||
|
DTXSID40152734
Created by
admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD